- Report
- March 2024
- 188 Pages
Global
From €3251EUR$3,374USD£2,797GBP
€3612EUR$3,749USD£3,107GBP
- Report
- October 2023
- 190 Pages
Global
From €4722EUR$4,900USD£4,061GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1204EUR$1,250USD£1,036GBP
- Report
- January 2024
- 200 Pages
Global
From €3999EUR$4,150USD£3,440GBP
- Report
- April 2023
- 110 Pages
Global
From €4577EUR$4,750USD£3,937GBP
- Report
- January 2022
- 60 Pages
Global
From €3806EUR$3,950USD£3,274GBP
- Report
- January 2022
- 200 Pages
Global
From €7227EUR$7,500USD£6,217GBP
- Drug Pipelines
- January 2019
- 60 Pages
Global
From €1927EUR$2,000USD£1,658GBP
- Report
- June 2022
- 120 Pages
Global
From €2409EUR$2,500USD£2,072GBP
- Drug Pipelines
- October 2020
- 137 Pages
Global
From €1927EUR$2,000USD£1,658GBP
- Report
- February 2024
- 90 Pages
Global
From €3500EUR$3,891USD£3,116GBP
- Report
- August 2022
- 81 Pages
Global
From €1927EUR$2,000USD£1,658GBP
Hairy Cell Leukemia (HCL) is a rare type of chronic leukemia that affects the B-lymphocytes, a type of white blood cell. Treatment for HCL typically involves chemotherapy, radiation therapy, and/or targeted therapy. Drug therapy is the most common form of treatment for HCL, and there are several drugs available on the market. These drugs are designed to target the abnormal B-lymphocytes and stop them from growing and dividing. Commonly used drugs for HCL include cladribine, pentostatin, and rituximab.
The HCL drug market is a small but growing segment of the larger leukemia drug market. It is composed of several companies that specialize in the development and manufacture of drugs for HCL. These companies include Celgene, Novartis, Merck, and Genentech. Each of these companies has developed drugs that are approved for the treatment of HCL, and they are continually researching and developing new treatments for the disease. Show Less Read more